<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZOLMITRIPTAN</span><br/>(zol-mi-trip'tan)<br/><span class="topboxtradename">Zomig, </span><span class="topboxtradename">Zomig ZMT, </span><span class="topboxtradename">Zomig Nasal Spray<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha-adrenergic antagonist (sympatholytic)</span>; <span class="classification">serotonin 5-ht<sub>1b/1d</sub> receptor agonist</span>; <span class="classification">ergot alkaloid</span><br/><b>Prototype: </b>Sumatriptan<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg, 5 mg tablets orally disintegrating tablets; 5 mg nasal spray</p>
<h1><a name="action">Actions</a></h1>
<p>Selective serotonin (5-HT<sub>1B/1D</sub>) receptor agonist. The agonist effects at 5-HT<sub>1B/1D</sub> reverse the vasodilation of cranial blood vessels associated with a migraine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Activation of these receptors also reduces the pain pathways associated with migraine headache in addition to causing vasoconstriction
         of the cranial blood vessels.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute migraine headaches with or without aura.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to zolmitriptan; ischemic heart disease (angina pectoris, arteriosclerosis, ECG changes, history of MI or
         Prinzmetal's angina); cardiac arrhythmias, symptomatic Wolff-Parkinson-White syndrome, uncontrolled hypertension; hemiplegia
         or basilar migraine; concurrent administration of ergotamine or sumatriptan; PKU; adults &gt;65 y; pregnancy (category C); children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Men &gt;40 y; postmenopausal women; patients with other cardiac risk factors, such as diabetes, obesity, cigarette smoking, high
         cholesterol levels, strong family history of CAD; GI disease, PVD, ischemic colitis, Raynaud's disease, cerebrovascular disease,
         stroke, intracranial bleeding; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Migraine</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.55 mg, may repeat in 2 h if necessary (max: 10 mg/24 h) <span class="rdroute">Nasal Spray</span> One spray into one nostril<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give any time after symptoms of migraine appear. Give <img src="../images/special/lesserorequal.gif"/>2.5 mg by breaking a
            5 mg tablet in half. If headache returns, may repeat q2h up to 10 mg in 24 h.
         </li>
<li>Do <small>NOT</small> give zolmitriptan within 24 h of an ergot-containing drug or other 5-HT<sub>1</sub> agonist.
         </li>
<li>Discard unused tablets that have been removed from the packaging.</li>
</ul><span class="adminroutetype">Intranasal</span><br/><ul>
<li>Unit-dose spray device delivers a 5 mg dose. Do not exceed the maximum dose of 10 mg in 24 h.</li>
<li>Store at 2°25° C (36°77° F) and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Asthenia, fatigue, malaise, pain, pressure sensation, paresthesia, throat pressure, warm/cold sensations, hypesthesia. <span class="typehead">CNS:</span> Somnolence, dizziness, drowsiness, headache, hypesthesia, decreased mental acuity, euphoria, tremor. <span class="typehead">CV:</span> Coronary artery vasospasm, transient myocardial ischemia, <span class="speceff-life">MI</span>, ventricular tachycardia, ventricular fibrillation, chest pain/tightness/heaviness, palpitations. <span class="typehead">GI:</span> Dry mouth, nausea, vomiting. <span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead">Skin:</span> Flushing. <span class="typehead">Other:</span> Hot flushes. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Dihydroergotamine,</b> <b>methysergide,</b> other 5-<span class="classification">HT<sub>1</sub> agonists</span> may cause prolonged vasospastic reactions; <span class="classification">ssris</span> have rarely caused weakness, hyperreflexia, and incoordination; <span class="classification">maoi</span>s should not be used with 5-HT<sub>1</sub> agonists; <b>cimetidine</b> increases half-life of zolmitriptan. <span class="typehead">Herbal:</span> <b>St. John's wort</b> may increase triptan toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed, 40% bioavailability. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> 25% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolite. <span class="typehead">Elimination:</span> Excreted primarily in urine (65%), 30% excreted in feces. <span class="typehead">Half-Life:</span> 3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Relief or reduction of migraine pain within 14 h.</li>
<li>Monitor cardiovascular status carefully following first dose in patients at risk for CAD (e.g., postmenopausal women, men
            &gt;40 y, persons with known CAD risk factors) or coronary artery vasospasms.
         </li>
<li>Perform periodic cardiovascular evaluation and ECG with long-term use.</li>
<li>Report to physician immediately chest pain, nausea, or tightness in chest or throat that is severe or does not quickly resolve.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Carefully review patient information insert and guidelines for taking drug.</li>
<li>Do <small>NOT</small> take zolmitriptan during the aura phase, but as early as possible after onset of migraine.
         </li>
<li>Concurrent oral contraceptive use may increase incidence of adverse effects.</li>
<li>Contact physician immediately if any of the following occur after zolmitriptan use: Symptoms of angina (e.g., severe or persistent
            pain or tightness in chest or throat, sudden nausea), hypersensitivity (e.g., wheezing, facial swelling, skin rash, hives),
            fainting, or abdominal pain.
         </li>
<li>Report any other adverse effects (e.g., tingling, flushing, dizziness) at next physician visit.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>